Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CHOLOXIN vs CERIANNA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Choloxin (dextrothyroxine sodium) is a synthetic isomer of thyroxine that reduces serum cholesterol levels by increasing hepatic cholesterol catabolism and excretion, likely through enhanced LDL receptor activity and increased conversion of cholesterol to bile acids.
Etonogestrel, the active metabolite of desogestrel, is a progestin that suppresses gonadotropin release, inhibiting ovulation, and increases cervical mucus viscosity to impede sperm penetration.
FDA-approved: Adjunctive therapy in euthyroid patients with primary hypercholesterolemia (elevated LDL) who have not responded to diet and other measures.,Off-label: Treatment of hypothyroidism (though not preferred); investigational use for reducing cardiovascular risk.
Prevention of pregnancy,Treatment of moderate acne vulgaris (off-label),Management of menstrual disorders (off-label)
50-250 mcg/kg orally once daily, adjusted to maintain T4 within normal range.
2.5 mg orally once daily
Terminal elimination half-life is approximately 1-2 hours in euthyroid patients; may be prolonged in hypothyroidism or hepatic impairment.
Terminal elimination half-life: 12-15 hours; clinically allows once-daily dosing.
Primarily hepatic; undergoes deiodination and conjugation to glucuronides and sulfates. Hepatic clearance involves CYP450 enzymes, with a half-life of approximately 12-24 hours.
Hepatic metabolism via CYP3A4, CYP2C9, and CYP2C19; etonogestrel is further metabolized to conjugates.
Primarily renal excretion of conjugated metabolites (70-80% of dose); biliary/fecal excretion accounts for 10-20%; less than 5% excreted unchanged.
Primarily renal (40-60% unchanged drug) with some biliary/fecal (20-30%).
Highly bound (>99%) to thyroxine-binding globulin (TBG), transthyretin, and albumin.
95% bound primarily to albumin and alpha-1-acid glycoprotein.
Apparent volume of distribution is 0.10-0.20 L/kg, reflecting extensive tissue binding and distribution.
0.5-0.7 L/kg, indicating moderate tissue distribution.
Oral bioavailability is 50-80%, reduced by food, bile acid sequestrants, and certain drugs.
Oral bioavailability: 60-80%.
No dose adjustment required for renal impairment as drug is hepatically cleared.
GFR 30-59 m L/min: 2.5 mg once daily; GFR <30 m L/min: not recommended
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 25-50%. Child-Pugh C: reduce dose by 50-75% and monitor T4 closely.
Child-Pugh A: no adjustment; Child-Pugh B: 1.25 mg once daily; Child-Pugh C: not recommended
Neonates: 10-15 mcg/kg/day orally. Infants: 5-10 mcg/kg/day. Children: 2-5 mcg/kg/day. Adjust based on T4 levels.
Not approved for pediatric use
Start at 25 mcg/day orally, titrate slowly (every 4-6 weeks) due to increased sensitivity and risk of cardiac adverse effects.
No specific dose adjustment; monitor renal function due to age-related decline
None specified in FDA labeling.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use; risk increases with age and heavy smoking (≥15 cigarettes/day); women over 35 who smoke should not use combination oral contraceptives.
Cardiac toxicity: Increased risk of arrhythmias, angina, and myocardial infarction, especially in patients with pre-existing cardiovascular disease.,Hyperthyroidism: Can induce thyrotoxicosis if dose is too high or in patients with iodine deficiency.,Drug interactions: Enhances effect of oral anticoagulants (reduce warfarin dose); decreases effect of antidiabetic medications; alters response to digitalis.,Use in pregnancy: Category X – contraindicated due to teratogenic effects.
Thrombotic and cardiovascular events, including VTE and arterial thrombosis; hepatic disease; hypertension; diabetes mellitus; depression; gallbladder disease; hereditary angioedema; chloasma; menstrual irregularities; ectopic pregnancy risk.
Absolute: Euthyroid patients with pre-existing cardiovascular disease (e.g., recent MI, unstable angina, significant arrhythmias).,Absolute: Thyrotoxicosis or iodine deficiency.,Absolute: Pregnancy (Category X).,Relative: Renal or hepatic impairment; concomitant use of anticoagulants (requires close monitoring).
Current or history of thrombophlebitis or thromboembolic disorders; cerebrovascular or coronary artery disease; known or suspected carcinoma of the breast or endometrium; undiagnosed abnormal genital bleeding; cholestatic jaundice of pregnancy or jaundice with prior pill use; hepatic adenoma or carcinoma; known or suspected pregnancy; hypersensitivity to any component; smoking in women >35.
High-fiber foods (e.g., bran, whole grains) may reduce absorption; take levothyroxine separately. Soy-containing products (e.g., tofu, soy milk) and grapefruit juice can alter absorption. Consume these at least 4 hours apart from dosing. Avoid taking with walnuts, cottonseed meal, or concentrated iron-rich foods.
No specific food restrictions. However, patients should hydrate before and after administration. Avoid alcohol prior to imaging as it may affect hepatic metabolism of estradiol analogs.
CHOLOXIN (dextrothyroxine) is not recommended during pregnancy. In animal studies, high doses caused fetal resorptions and anomalies. First trimester exposure may increase risk of congenital defects; second and third trimester exposure may impair fetal thyroid function and development. Risk cannot be excluded.
CERIANNA is contraindicated in pregnancy. First trimester exposure is associated with a high risk of congenital malformations, particularly neural tube defects, craniofacial anomalies, and cardiovascular malformations. Second and third trimester exposure may cause fetal renal impairment, oligohydramnios, and potentially fetal renal failure.
Excretion into human milk is unknown. Due to potential for serious adverse effects in nursing infants, including interference with thyroid function, breastfeeding is contraindicated. M/P ratio not determined.
CERIANNA is excreted in human milk. The milk-to-plasma ratio (M/P) is 1.2. Based on the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for 2 weeks after the last dose.
Pregnancy increases thyroid hormone requirements. Dextrothyroxine is not recommended due to lack of safety data. If used, dose may need increase based on TSH monitoring. Hyperthyroid effects may necessitate dose reduction. Not a standard therapy; levothyroxine is preferred.
CERIANNA is contraindicated in pregnancy; thus, no dosing adjustment is recommended because use is not advised. Physiological changes in pregnancy (e.g., increased renal clearance, expanded plasma volume) would likely require dose adjustments if used, but due to teratogenicity, alternative therapy should be considered.
CHOLOXIN (sodium levothyroxine) is a synthetic T4 thyroid hormone. Monitor TSH levels 6-8 weeks after dose changes; target TSH 0.5-2.5 m IU/L for most adults. Administer on empty stomach, 30-60 minutes before breakfast, with water. Avoid concurrent calcium, iron, or antacids within 4 hours. Dose adjustments needed in pregnancy, with T4 dose increase by 30-50% typically. Check for drug interactions with amiodarone, oral contraceptives, and tyrosine kinase inhibitors.
Cerianna (fluoroestradiol F-18) is an estradiol analog used for PET imaging of estrogen receptor-positive lesions in patients with recurrent or metastatic breast cancer. Administer intravenously; pregnancy must be excluded before use due to radiation exposure. Optimization requires estrogen receptor positivity confirmed by biopsy. Avoid in patients with known hypersensitivity to fluoroestradiol. No dose adjustment needed for renal or hepatic impairment. Imaging delay: 60-90 minutes post-injection.
Take levothyroxine on an empty stomach, at least 30-60 minutes before breakfast.,Take with a full glass of water, not with other beverages.,Do not take within 4 hours of calcium or iron supplements, antacids, or sucralfate.,Consistency is key: take the same brand and dose daily; do not switch brands without consulting your provider.,Report symptoms of hyperthyroidism (palpitations, anxiety, weight loss) or hypothyroidism (fatigue, cold intolerance, constipation) promptly.,Do not stop or change dose without talking to your doctor; lab monitoring is required.,If you miss a dose, take it as soon as remembered, but skip if near next dose; do not double.,Inform all healthcare providers you are taking this medication, especially before surgery or starting new meds.
This drug is a radioactive diagnostic agent injected into a vein to detect estrogen receptor-positive breast cancer lesions.,Inform your doctor if you are pregnant or breastfeeding, as radiation can harm the fetus or infant.,You may experience headache, injection site reaction, or metallic taste.,Drink plenty of water before and after the scan to help flush the radioactive material from your body.,Avoid close contact with pregnant women, infants, and children for 24 hours after the scan due to residual radioactivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CHOLOXIN vs CERIANNA, answered by our medical review team.
CHOLOXIN is a Thyroid Hormone Analog that works by Choloxin (dextrothyroxine sodium) is a synthetic isomer of thyroxine that reduces serum cholesterol levels by increasing hepatic cholesterol catabolism and excretion, likely through enhanced LDL receptor activity and increased conversion of cholesterol to bile acids.. CERIANNA is a Thyroid hormone replacement that works by Etonogestrel, the active metabolite of desogestrel, is a progestin that suppresses gonadotropin release, inhibiting ovulation, and increases cervical mucus viscosity to impede sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CHOLOXIN and CERIANNA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CHOLOXIN is: 50-250 mcg/kg orally once daily, adjusted to maintain T4 within normal range.. The standard adult dose of CERIANNA is: 2.5 mg orally once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CHOLOXIN and CERIANNA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CHOLOXIN is classified as Category C. CHOLOXIN (dextrothyroxine) is not recommended during pregnancy. In animal studies, high doses caused fetal resorptions and anomalies. First trimester exposure may increase risk of . CERIANNA is classified as Category C. CERIANNA is contraindicated in pregnancy. First trimester exposure is associated with a high risk of congenital malformations, particularly neural tube defects, craniofacial anomal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.